Mylan sues Celgene for blocking Revlimid, Thalomid generics

[Reuters] – Mylan Inc on Thursday sued Celgene Corp to stop the latter’s effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market. The lawsuit accuses Celgene of maintaining unlawful monopolies over Revlimid, more

View todays social media effects on CELG

View the latest stocks trending across Twitter. Click to view dashboard

See who Celgene is hiring next, click here to view